Key facts
- This page summarizes Alexander A. Fitzpatrick's Form 4 filing for ARS Pharmaceuticals, Inc. (SPRY).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 05 Jan 2026, 16:25.
Alexander A. Fitzpatrick - 02 Jan 2026 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)
- Reporting relationship
- Chief Legal Officer
- Issuer ticker
- SPRY
- Reported as of
- 02 Jan 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Jan 2026, 16:25:06 UTC
- Prior SEC filing
- 22 May 2025
- Next SEC filing
- 12 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kathleen Scott, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Alexander A. Fitzpatrick filed Form 4 for ARS Pharmaceuticals, Inc. (SPRY) on 05 Jan 2026.
Change
- Previous filing in this sequence was filed on 22 May 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001398595
Primary reporting owner
Fitzpatrick Alexander A
- Relationship
- Chief Legal Officer
- Address
- C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
- Signature
- /s/ Kathleen Scott, Attorney-in-Fact
- Signature date
- 05 Jan 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SPRY
transaction
Derivative
Stock option (right to buy)
Award
- Transaction value
- $0
- Shares
- +240,000
- Change %
- Price
- $0.000000
- Shares after
- 240,000
- Date
- 02 Jan 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 240,000
- Exercise price
- $11.49
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026.